Stem Pharm, Inc

stempharm.com

Stem Pharm offers unique biomaterials for cell and tissue manufacturing. Applications include medical devices for drug discovery, cell therapy, and regenerative medicine. Stem Pharm's synthetic biomaterials support the optimization of cell expansion and differentiation, human tissue formation and cell/tissue delivery applications. Through control of the biomaterial properties (e.g. mechanical stiffness, cell adhesion, degradability), and utilizing chemistries that maintain cellular health and function, we provide cell-specific biomaterials to researchers and clinicians to fill unmet needs in their workflows. Currently, cell and tissue manufacturing processes often rely on animal-derived biomaterials that are complex and variable in nature and problematic for human in vivo applications due to potential pathogen transmission or an immunogenic response. Our materials are synthetic, defined, and optimized to produce functional cells and tissues and deliver them to areas of clinical need.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industry Outlook

MAGENTA THERAPEUTICS AND DIANTHUS THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Globenewswire | May 04, 2023

news image

Magenta Therapeutics, Inc. and Dianthus Therapeutics, Inc. a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103 currently in a Phase 1 clinical trial. Upo...

Read More

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

news image

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More

MedTech

LYSANDO AG AND AMICOGEN INC. SIGN GENERAL DEVELOPMENT AGREEMENT

Lysando AG and Amicogen Inc. | October 19, 2022

news image

Lysando AG market leader in the field of antimicrobial proteins has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea. In August last year, Lysando and Amicogen entered into a strategic partnership backed up by a mutual participation model. This collaboration has since been further intensified, now culminating in aforementioned general development agreement. " Read More

GENAPSYS RAISES $75M TO BRING ITS TABLETOP DNA SEQUENCER TO ASIA AMID CORONAVIRUS OUTBREAK

FierceBiotech | February 06, 2020

news image

Just months after collecting $90 million to support the launch of its compact DNA sequencing hardware, GenapSys has raised another $75 million to finance its global expansion with its eyes set on the Asia-Pacific market and the expanding coronavirus outbreak. The company’s high-throughput sequencer—which sits on a tabletop and weighs less than 10 pounds—is being launched in South Korea, Singapore, Japan and China as part of more than 25 recently inked distribution deals....

Read More
news image

Industry Outlook

MAGENTA THERAPEUTICS AND DIANTHUS THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Globenewswire | May 04, 2023

Magenta Therapeutics, Inc. and Dianthus Therapeutics, Inc. a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103 currently in a Phase 1 clinical trial. Upo...

Read More
news image

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More
news image

MedTech

LYSANDO AG AND AMICOGEN INC. SIGN GENERAL DEVELOPMENT AGREEMENT

Lysando AG and Amicogen Inc. | October 19, 2022

Lysando AG market leader in the field of antimicrobial proteins has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea. In August last year, Lysando and Amicogen entered into a strategic partnership backed up by a mutual participation model. This collaboration has since been further intensified, now culminating in aforementioned general development agreement. " Read More

news image

GENAPSYS RAISES $75M TO BRING ITS TABLETOP DNA SEQUENCER TO ASIA AMID CORONAVIRUS OUTBREAK

FierceBiotech | February 06, 2020

Just months after collecting $90 million to support the launch of its compact DNA sequencing hardware, GenapSys has raised another $75 million to finance its global expansion with its eyes set on the Asia-Pacific market and the expanding coronavirus outbreak. The company’s high-throughput sequencer—which sits on a tabletop and weighs less than 10 pounds—is being launched in South Korea, Singapore, Japan and China as part of more than 25 recently inked distribution deals....

Read More